Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

There was HKD2 billion, HKD779 million and HKD556.9 million Southbound Trading net inflow to TRACKER FUND (02800.HK), AKESO ...

ET Net News Agency, 28 April 2025] Nomura raised the target price for Akeso (09926) to HKD99.66 from HKD75.14 and downgraded the rating to "neutral" from "buy". The research hous ...

As trade tensions between the U.S. and China show signs of easing, Asian markets are experiencing a renewed sense of optimism, particularly in the technology sector where growth prospects remain ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

AKESO (09926.HK) -11.700 (-11.830%) Short selling $708.06M; Ratio 13.956% sank to a bottom of $84.1. It last traded at $84.1, ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...